QNRX_OUT_1 [2025-04-02 07:51:55 -0400] 3027 Bytes | 747 tokens | Cum: 747 tkns (9.34% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 7:51:55 AM on Wed Apr 02, 2025 -0400, and I'm firing up the spotlight on Quoin Pharmaceuticals (QNRX), moving from 0.2116 to 0.2779. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Quoin Pharmaceuticals (QNRX)
IPO: 2021-10-28 (3 Years Ago)
Market Cap: $4,355,962
Shares Outstanding: 20,590,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Here's the first list of news for Quoin Pharmaceuticals:

C1 - Today 07:30AM - Quoin Pharmaceuticals Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
C2 - Mar-25-25 07:30AM - Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
C3 - Mar-13-25 07:30AM - Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
C4 - Mar-06-25 08:00AM - Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
C5 - Mar-04-25 07:30AM - Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
C6 - Feb-27-25 07:30AM - Quoin Pharmaceuticals Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study
C7 - Feb-25-25 07:30AM - Quoin Pharmaceuticals Launches First Episode of "NETHERTON NOW" Video Series to Raise Awareness for Netherton Syndrome
C8 - Feb-04-25 07:30AM - Quoin Pharmaceuticals Launches 'NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Quoin Pharmaceuticals (QNRX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

QNRX_OUT_3 [2025-04-02 07:51:58 -0400] 1107 Bytes | 310 tokens | Cum: 1059 tkns (13.24% of 8k)
==========================================================================

Showing C1 (chunk 1 of 10): C1:
**Quoin Pharmaceuticals Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient**
Date: Today 07:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/02/3054146/0/en/Quoin-Pharmaceuticals-Announces-Additional-Positive-Whole-Body-Clinical-Data-from-Ongoing-Pediatric-Netherton-Syndrome-Study-and-Approval-to-Initiate-Testing-of-a-Second-Pediatric-.html

April 02, 2025 07:30 ET| Source:Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals, Inc.

ASHBURN, Va., April 02, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces addition

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

QNRX_OUT_5 [2025-04-02 07:51:59 -0400] 1015 Bytes | 289 tokens | Cum: 1407 tkns (17.59% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T12:56:29Z - Market Outlook: What To Expect This Week - eBay (NASDAQ:EBAY), American International Gr (NYSE:AIG)...
A2 - 2025-03-28T16:08:25Z - QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles By Investing.com...
A3 - 2025-03-25T11:57:32Z - Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherto...
A4 - 2025-03-25T11:53:20Z - Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherto...
A5 - 2025-03-25T11:32:54Z - Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat ......

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

QNRX_OUT_7 [2025-04-02 07:52:01 -0400] 321 Bytes | 94 tokens | Cum: 1503 tkns (18.79% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1):

[INFO] Your document request exceeded 20000 characters. If you need more, please request additional documents separately.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

QNRX_OUT_9 [2025-04-02 07:52:02 -0400] 1130 Bytes | 312 tokens | Cum: 1850 tkns (23.12% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-07T19:29:00Z - PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials
B2 - 2024-06-25T20:05:00Z - Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
B3 - 2024-06-12T12:00:00Z - Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
B4 - 2024-05-02T20:10:00Z - Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
B5 - 2024-03-15T17:00:15Z - Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know
B6 - 2024-03-13T20:05:00Z - Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

QNRX_OUT_11 [2025-04-02 07:52:05 -0400] 1086 Bytes | 271 tokens | Cum: 2123 tkns (26.54% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/07/3005784/0/en/PRISM-MarketView-Spotlights-Quoin-Pharmaceuticals-CEO-Dr-Michael-Myers-as-Specialty-Pharma-Shares-News-of-Highly-Positive-Interim-Data-in-Most-Advanced-Comprehensive-Netherton-Synd.htmlQuoin Pharmaceuticals announced highly positive interim data from its ongoing Netherton Syndrome clinical trials, with the first subject demonstrating marked improvements across all measured endpoints after 12 weeks of treatment with the company's QRX003 topical lotion. The company is optimistic about the therapy's potential to effectively treat this rare and debilitating skin disease.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

QNRX_OUT_13 [2025-04-02 07:52:06 -0400] 1098 Bytes | 288 tokens | Cum: 2486 tkns (31.08% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-13 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our audited CONS financial statements and related...

S2 - 2025-03-13 8-K Item 2.02 Results of Oper and Fin Cond.

On March 13, 2025 Quoin Pharmaceuticals Ltd. (the Company) announced its fourth quarter and fiscal year 2024 financial results. A copy of the Companys press release is attached as Exhibit 99.1 hereto and incorporated by r...

S3 - 2024-12-26 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On December 23, 2024, Quoin Pharmaceuticals Ltd. (the Company), co mpleted a public offering (the Offering) of an aggregate of: (i) 3,137,778 ordinary shares, no par value, of the Company (Ordinary Shares) represented by Am...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

QNRX_OUT_15 [2025-04-02 07:52:07 -0400] 1098 Bytes | 224 tokens | Cum: 2712 tkns (33.90% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our audited consolidated financial statements and related notes to those statements included in this Annual Report. Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP), reflect the operations of Quoin Pharmaceuticals Inc. (Quoin Inc.) since inception and include the accounts of Quoin Ltd. since the closing of the Merger (as defined below). In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs and expectations that involve risks and uncertainties. Our actual results and the timi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

QNRX_OUT_17 [2025-04-02 07:52:12 -0400] 1098 Bytes | 230 tokens | Cum: 2944 tkns (36.80% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ng of events could differ materially from those discussed in these forward-looking statements. Important factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in Part I, Item 1A. Risk Factors and the section entitled Cautionary Note Regarding Forward-Looking Statements and Summary of Risk Factors.

Overview

We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently no approved treatments or cures. Our initial focus is on the development of products, using our proprietary owned and in-licensed drug delivery technologies, that could help address rare genetic diseases. Our lead product, QRX003, is under clinical development as a potential treatment for Netherton S

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

QNRX_OUT_19 [2025-04-02 07:52:24 -0400] 4078 Bytes | 1150 tokens | Cum: 4206 tkns (52.58% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+----------------------+
| Volume: 406,526 | Perf Month: -30.17% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 5.38M | Perf Quarter: -61.53% | Short Float: 17.27% | ROE: -121.15% |
+--------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.07 | Index: - | Short Ratio: 0.16 | ROI: -97.85% |
+--------------------+-----------------------+------------------------+----------------------+
| RSI (14): 28.21 | Market Cap: 1.89M | Short Interest: 0.87M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.03 | Shs Outstand: 8.95M | Beta: 1.39 | EPS Surprise: 23.91% |
+--------------------+-----------------------+------------------------+----------------------+
| SMA20: -26.34% | Shs Float: 5.03M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+----------------------+
| SMA50: -33.56% | Inst Own: 17.28% | Sales past 5Y: 0.00% | Earnings: Mar 13 BMO |
+--------------------+-----------------------+------------------------+----------------------+
| SMA200: -61.54% | Insider Own: - | Employees: 5 | |
+--------------------+-----------------------+------------------------+----------------------+
| Perf Week: -24.75% | Insider Trans: - | Debt/Eq: 0.00 | |
+--------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -8962472.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.2116
Average Volume: 547376.91
30-Day High: 0.324
30-Day Low: 0.2116

[Detailed Financials: TTM 2024]
- Total Assets: $15,709,338.0
- Total Liabilities: $6,504,665.0
- Total Equity: $9,204,673.0
- Current Assets: $14,926,004.0
- Current Liabilities: $4,180,932.0

[Income Statement: TTM 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $1,222,145.0

[Detailed Financials: FY 2024]
- Total Assets: $15,709,338.0
- Total Liabilities: $6,504,665.0
- Total Equity: $9,204,673.0
- Current Assets: $14,926,004.0
- Current Liabilities: $4,180,932.0

[Income Statement: FY 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $1,222,145.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

QNRX_OUT_21 [2025-04-02 07:52:27 -0400] 676 Bytes | 167 tokens | Cum: 4612 tkns (57.65% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

QNRX_IN_23 [2025-04-02 07:52:28 -0400] 126 Bytes | 29 tokens | Cum: 4725 tkns (59.06% of 8k)
==========================================================================

====================================
[2025-04-02 07:52:28] # Analysis Completed
Elapsed Time: 33.05 seconds